

LIVING WELL WITH PARKINSON'S DISEASE

Winter 2026

Roche to Advance Prasinezumab into Phase III Development for Early-Stage PD

[excerpted from: www.rosche.com](http://www.rosche.com)



Roche announced to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage PD. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two phase II trials and their open-label extensions, combined with the favorable safety and tolerability profile of prasinezumab," said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development at Roche. "We also recognize the substantial need for new treatment options, and the totality of data suggest that prasinezumab may have the potential to become the first disease-modifying treatment for people with PD." Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage PD. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage PD, are ongoing. Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease.

Data from the Phase IIb PADOVA study suggests the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage PD. PADOVA investigated prasinezumab in 586 people with early-stage PD, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance ($p=0.0657$). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], $p=0.0431$ (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa treated populations. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 PD study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. Roche entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of PD.

Parkinson's Patient Support Group
Meets the third Tuesday of every month from 2:00PM-3:30PM.

Parkinson's Care Partners Support Group
Meets the first Wednesday of every month from 2:00PM-3:30PM.

Deep Brain Stimulation (DBS) Informational Sessions
Meets on the first Friday of February from 1:00PM-2:00PM and every three months thereafter.

Deep Brain Stimulation (DBS) Support Group
Meets the third Wednesday of every month from 2:00PM-3:30PM.

Connecting Through Art
Meets the fourth Monday of every month from 2:00PM-3:30PM.

Access to Care Orientation
Meets the second Wednesday of every month from 1:00PM-2:00PM.

To register for any of the above programs, please contact Erika Adelman, LCSW, SIFI at 929-695-0282 or via email at era2142@cumc.columbia.edu.

Music and Movement Virtual Concert Series
Meets the first and third Monday of every month from 5:00PM-5:45PM. To register, please contact Vedhika Basavatia at 929-274-0771.

Speech for PD
Meets every Tuesday and Thursday from 11:15AM-12:30PM. For more information and to register, please contact Gemma Moya-Gale, Ph.D., CCC-SLP at gm2446@tc.columbia.edu.

Grupo de Apoyo Mensual Para La Comunidad Hispana
Se reúne todos los lunes de 1:30PM-3:00PM. Para obtener más información e inscribirse, póngase en contacto con Gemma Moya-Gale, Ph.D., CCC-SLP at gm2446@tc.columbia.edu.

Introducing Teacher's College's Newest Program: Promoting Physical Activity in People with Parkinson's Disease Program



Aim: To provide education and resources on the benefits of physical activity and other lifestyle factors that can help you live and thrive with Parkinson's Disease

What's Involved: You will take part in 2-6 sessions of physical activity coaching as well as complete questionnaires

Who Can Take Part: People who are...

- 18-85 years old
- Have a diagnosis of Parkinson's Disease
- Are able to walk indoors and outdoors independently
- Are free from any injuries that would prevent you from taking part in physical activity
- Reside in Upper Manhattan, Bronx, and surrounding areas nearby Columbia

Interested in participating? Please call 212- 678-3916 or send at email to neurorehablab@tc.columbia.edu



Interested in learning more about CUIMC's current research studies and clinical trials?

Please contact our research team at 347-882-4315 or via email at mdresearch@cumc.columbia.edu.

Division of Movement Disorders

Columbia University
Irving Medical Center
710 West 168th Street
New York, NY 10032

212-305-1303
[www.columbianeurology.org/
patient-care/movement-
disorders](http://www.columbianeurology.org/patient-care/movement-disorders)

Parkinson's Foundation National Hotline:

1-800-473-4636

Make a Gift--Make a Difference

Wish to Donate?...

Should you be interested in discussing how you can help support our clinical, research, and patient care activities, please contact Matthew Reals, Senior Director of Development, at **646-761-0915** or mr3134@columbia.edu.



Introducing NYP's Newest Facility: The One

NewYork-Presbyterian announced the opening of NewYork-Presbyterian's The One, a new center for advanced care in Westchester where world-class doctors from Columbia are now providing exceptional, comprehensive care for adults and children. The 225,000-square foot facility, centrally located in White Plains at 1111 Westchester Avenue, is offering adult and pediatric care spanning more than 90 specialties and sub-specialties, so patients can find the care they and their families need in one convenient location. At our new site, we have several LSVT certified rehab clinicians who are now providing OT, PT, and ST to the Parkinson's community. If you are interested in making an appointment with a member of The One's rehab team, please call 914-229-5020.

On behalf of the Movement Disorders Division at Columbia University Irving Medical Center and the Parkinson's Foundation, we would like to thank you for your ongoing participation in our Parkinson's program and clinical trials!



Happy Holidays and we wish you and your loved ones nothing but the best in the new year!

If you have a question regarding Parkinson's and its treatment that you would like featured in the next newsletter, please e-mail your questions and/or inquiries to Erika Adelman, LCSW, SIFI at era2142@cumc.columbia.edu.

The information published in this newsletter is not intended to replace, and should not be interpreted or relied upon, as professional advice, whether medical or otherwise. Please refer to your own professional for all advice concerning legal, medical, or other matters published in connection with this article.

"Don't count the days, make the days count."

-Muhammad Ali, diagnosed with PD in 1984